PAVMED INC. (NASDAQ:PAVMU) Files An 8-K Regulation FD Disclosure
Item 7.01.
| Regulation FD Disclosure. |
Attached as exhibit 99.1 to this Current Report is an updated
investor presentation that PAVmed Inc. (the Company) plans to use
for future investor meetings, public relations and other
corporate purposes.
The information furnished under this Item 7.01,including the
exhibit related thereto, shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, nor shall
it be deemed incorporated by reference in any disclosure document
of the Company, except as shall be expressly set forth by
specific reference in such document.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits:
| Exhibit | Description | |
| 99.1 | Investor Presentation. |
About PAVMED INC. (NASDAQ:PAVMU)
PAVmed Inc. is a medical device company. The Company’s products include PortIO, Caldus, CarpX, NextCath and NextFlo. PortIO is a long-term implantable vascular access device, which does not require accessing the central venous system and does not have an indwelling intravascular component. Caldus is a disposable tissue ablation device, which can also be used for renal denervation to treat hypertension. CarpX is a percutaneous device to treat carpal tunnel syndrome. NextCath is a self-anchoring catheter, which does not require suturing, traditional anchoring techniques or add-on catheter securement devices. The Company is developing disposable infusion pumps using stored potential energy and variable flow resistors. The Company has completed proof-of-concept work, thermal fine element analysis simulations validating its approach and working prototypes of the infusion device and balloon catheter. PAVMED INC. (NASDAQ:PAVMU) Recent Trading Information
PAVMED INC. (NASDAQ:PAVMU) closed its last trading session up +0.75 at 14.50 with 342 shares trading hands.
